Peter Mesenbrink

9.4k total citations · 1 hit paper
54 papers, 4.5k citations indexed

About

Peter Mesenbrink is a scholar working on Oncology, Orthopedics and Sports Medicine and Surgery. According to data from OpenAlex, Peter Mesenbrink has authored 54 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 30 papers in Orthopedics and Sports Medicine and 13 papers in Surgery. Recurrent topics in Peter Mesenbrink's work include Bone health and treatments (31 papers), Bone health and osteoporosis research (27 papers) and Hip and Femur Fractures (11 papers). Peter Mesenbrink is often cited by papers focused on Bone health and treatments (31 papers), Bone health and osteoporosis research (27 papers) and Hip and Femur Fractures (11 papers). Peter Mesenbrink collaborates with scholars based in United States, Switzerland and United Kingdom. Peter Mesenbrink's co-authors include Steven Boonen, Erik Fink Eriksen, Kenneth W. Lyles, Jay Magaziner, Cathleen Colón‐Emeric, Chris Recknor, Jonathan D. Adachi, Carl F. Pieper, Ian R. Reid and Lars Nordsletten and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Peter Mesenbrink

51 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

2007 1.4k citations Kenneth W. Lyles, Cathleen Colón‐Emeric et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Mesenbrink United States	28	3.1k	2.5k	1.0k	1.0k	612	54	4.5k
Beatrice J. Edwards United States	30	1.5k 0.5×	1.3k 0.5×	872 0.8×	402 0.4×	310 0.5×	90	3.4k
Pia Eiken Denmark	34	1.8k 0.6×	1.1k 0.4×	1.0k 1.0×	543 0.5×	96 0.2×	106	4.0k
Pernille Ravn Denmark	38	2.4k 0.8×	1.5k 0.6×	476 0.5×	1.1k 1.1×	60 0.1×	125	4.7k
H. A. P. Pols Netherlands	32	1.2k 0.4×	666 0.3×	563 0.5×	571 0.6×	118 0.2×	56	3.2k
Neil Gittoes United Kingdom	37	1.2k 0.4×	689 0.3×	1.2k 1.2×	790 0.8×	64 0.1×	124	4.5k
Tiina Saarto Finland	37	540 0.2×	2.6k 1.0×	460 0.4×	343 0.3×	146 0.2×	108	4.5k
Howard S. Barden United States	25	1.6k 0.5×	758 0.3×	572 0.6×	475 0.5×	69 0.1×	51	3.0k
Joan McGowan United States	19	1.6k 0.5×	1.3k 0.5×	882 0.9×	1.1k 1.1×	42 0.1×	30	3.5k
Harold N. Rosen United States	25	1.4k 0.4×	789 0.3×	393 0.4×	672 0.7×	43 0.1×	68	2.6k
W. Bensen Canada	26	828 0.3×	611 0.2×	779 0.8×	526 0.5×	69 0.1×	74	3.4k

Countries citing papers authored by Peter Mesenbrink

Since Specialization

Citations

This map shows the geographic impact of Peter Mesenbrink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Mesenbrink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Mesenbrink more than expected).

Fields of papers citing papers by Peter Mesenbrink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Mesenbrink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Mesenbrink. The network helps show where Peter Mesenbrink may publish in the future.

Co-authorship network of co-authors of Peter Mesenbrink

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Mesenbrink. A scholar is included among the top collaborators of Peter Mesenbrink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Mesenbrink. Peter Mesenbrink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Collins, Jamie E., Peter Mesenbrink, Erik B. Dam, et al.. (2025). Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression. ACR Open Rheumatology. 7(9). e70085–e70085. 1 indexed citations

Gidh‐Jain, Madhavi, et al.. (2024). Developing generic templates to shape the future for conducting integrated research platform trials. Trials. 25(1). 204–204. 5 indexed citations

Hees, Katharina, Franz König, Martin Posch, et al.. (2024). Regulatory Issues of Platform Trials: Learnings from EU‐PEARL. Clinical Pharmacology & Therapeutics. 116(1). 52–63. 7 indexed citations

Meyer, Elias Laurin, Peter Mesenbrink, Nicholas A. Di Prospero, et al.. (2023). Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints. PLoS ONE. 18(3). e0281674–e0281674. 5 indexed citations

Burman, Carl‐Fredrik, Ekkehard Glimm, Stefan M. Gold, et al.. (2022). On model-based time trend adjustments in platform trials with non-concurrent controls. BMC Medical Research Methodology. 22(1). 228–228. 30 indexed citations

Meyer, Elias Laurin, et al.. (2021). Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials. arXiv (Cornell University). 12 indexed citations

Meyer, Elias Laurin, Peter Mesenbrink, Cornelia Dunger‐Baldauf, et al.. (2020). The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics. 42(7). 1330–1360. 82 indexed citations

Yuan, Jiacheng, et al.. (2018). Clinical Study Design to Assess Both Short- and Long-term Efficacy in Addition to Group Sequential Test on Safety. Therapeutic Innovation & Regulatory Science. 52(6). 690–695.

Reid, Ian R., Dennis M. Black, Richard Eastell, et al.. (2013). Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams. The Journal of Clinical Endocrinology & Metabolism. 98(2). 557–563. 76 indexed citations

10.

Eastell, Richard, Dennis M. Black, Steven Boonen, et al.. (2010). Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density. Obstetrical & Gynecological Survey. 65(3). 177–178. 12 indexed citations

11.

Cauley, Jane A., Dennis M. Black, Steven Boonen, et al.. (2010). Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial. Journal of Bone and Mineral Research. 26(5). 984–992. 26 indexed citations

12.

Eriksen, Erik Fink, Kenneth W. Lyles, Cathleen Colón‐Emeric, et al.. (2009). Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture. Journal of Bone and Mineral Research. 24(7). 1308–1313. 100 indexed citations

13.

Delmas, Pierre D., F. Munoz, Dennis M. Black, et al.. (2009). Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis. Journal of Bone and Mineral Research. 24(9). 1544–1551. 90 indexed citations

14.

Reid, David M., Jean‐Pierre Devogelaer, Kenneth G. Saag, et al.. (2009). Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Trial): A Multicentre, Double-Blind, Double-Dummy, Randomized Controlled Trial. Obstetrical & Gynecological Survey. 64(8). 521–523. 1 indexed citations

15.

Eastell, Richard, Thomas Lang, Steven Boonen, et al.. (2009). Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporosis International. 21(7). 1277–1285. 38 indexed citations

16.

Sambrook, Philip N., Jean‐Pierre Devogelaer, J.-Y. Reginster, et al.. (2008). Effect of a Single 5-mg Infusion of Zoledronic Acid on Bone Turnover Markers Versus Oral Risedronate (5 mg/day) Over 1 Year in Patients with Glucocorticoid-Induced Osteoporosis.. Journal of Bone and Mineral Research. 23. 1 indexed citations

17.

Roux, C., Jean‐Pierre Devogelaer, Donald Reid, et al.. (2008). Effect of Zoledronic Acid (Single 5-mg Infusion) on Lumbar Spine Bone Mineral Density Versus Oral Risedronate (5 mg/day) Over 1 Year in Subgroups of Patients Receiving Glucocorticoid Therapy.. Journal of Bone and Mineral Research. 23. 1 indexed citations

18.

Boonen, Steven, Deborah E. Sellmeyer, Kurt Lippuner, et al.. (2008). Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney International. 74(5). 641–648. 88 indexed citations

19.

Recker, Robert R., Pierre D. Delmas, Johan Halse, et al.. (2007). Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure. Journal of Bone and Mineral Research. 23(1). 6–16. 170 indexed citations

20.

Eastell, Richard, Dennis M. Black, Jane A. Cauley, et al.. (2007). Effect of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis. 14. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact